Comparative Pharmacology
Head-to-head clinical analysis: RECORLEV versus THYQUIDITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RECORLEV versus THYQUIDITY.
RECORLEV vs THYQUIDITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
Thyroid hormone replacement; levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, regulating gene transcription and increasing metabolic rate.
150 mg orally twice daily with a high-fat meal.
50 mg orally once daily, with or without food.
None Documented
None Documented
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
The terminal elimination half-life of levothyroxine is approximately 6-7 days in euthyroid individuals. In hyperthyroidism, half-life decreases to 3-4 days; in hypothyroidism, it can extend to 9-10 days. This long half-life supports once-daily dosing and allows for steady-state achievement in about 6-8 weeks.
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Thyquidity (levothyroxine sodium) is primarily excreted via the kidneys as unchanged drug and metabolites. Approximately 20-40% of an oral dose is excreted in feces via biliary elimination, with the remainder eliminated renally. Up to 80% of an administered dose appears in urine as thyroxine and its metabolites, primarily glucuronide and sulfate conjugates.
Category C
Category C
Thyroid Hormone
Thyroid Hormone